Randomized controlled clinical trial of two modality treatments for refractory wound seroma after modified radical mastectomy

Document Type : Original Article

Authors

1 Department of Experimental and Clinical Surgery, Medical Research Institute.

2 Department of Surgery, University of Alexandria.


 

Randomized controlled clinical trial of two modality treatments for refractory wound seroma after modified radical mastectomy

 

 

Medhat Mohamed Anwar,a MD; Amr Alkobrosy,a MD; Mohamed Atef Motawei,a MD; Mohamed Gaber Ibrahim,b MD

 

 

a) Department of Experimental and Clinical Surgery, Medical Research Institute. b) Department of Surgery, University of Alexandria.

 

 

 

Introduction:

Seroma  formation is the  most  common complication following mastectomy)  It's incidence after breast surgery varies between

2.5% and 51%.2 Seroma is defined as a sterile accumulation of serum  in a circumscribed location in  the  tissue. It  develops at  the operative site beneath  the skin flaps during mastectomy  or in the axillary  dead space in the immediate or acute postoperative  period. It is the result of tissue insult and the product of tissue inflammation and the body's defense mechanisms. Refractory seroma is the seroma which persists more than one month or high output drainage for long period.3

Although seroma is not life threatening, it can lead  to significant morbidity (e.g. flap necrosis,  wound dehiscence, predisposes  to sepsis, prolonged recovery period, multiple physician visits) and  may  delay  adjuvant therapy.4

Management options  for seroma  can be described as preventive  or therapeutic. The former includes mechanical closure  of dead space,s intraoperative administration of sclerosant6 or  tissue glue  into  the  wound cavity7and insertion of postoperative vacuum drains.8 Therapeutic measures include percutaneous aspiration,9 excision of the seroma capsule,10 and administration of tissue gluell or sclerosant.12

Mechanism of action  of sclerotherapy is the induction of inflammatory response which leads to stimulation  of fibroblasts leading to fibrosis and cavity obliteration.6 Tetracycline, ethyl  alcohol  70%,13 povidone iodine  and erythromycin  have been used as sclerosants. Topical tetracycline has been proved to be not effective in preventing post-mastectomy wound seromas.6 As regard erythromycin which is a common antibiotic, it was found to have a side


effect in the form of irritation and inflammation at the site of injection if extravasation occurred It  has  been  used  safely in  humans  in  the management of malignant pleural effusions14 and non-neoplastic ovarian cysts.l 5 Povidone iodine has been used for chemical pleurodesis.16

Success  rates reported  ranged  from 64% to

100%.  Also, several groups have reported povidone iodine sclerotherapy for  post­ transplant lymphoceles.l7

This  study aims  at the evaluation of the efficiency of two sclerosants; erythromycin and povidone iodine in the treatment of post modified radical mastectomy (MRM) refractory seroma in comparison to standard mechanical drainage using  an indwelling catheter as a control group.

 

Methods:

Study design:

The study is a randomized controlled clinical trial.

Study setting:

The study was conducted in the Department of Surgery,  Medical Research  Institute,  and the  Main  University Hospital, Faculty of Medicine, University of Alexandria, from beginning of June 2009  till end of October

2010.

Study population:

All patients  suffering  from postoperative mastectomy refractory seromas were included in the study. They were randomly divided into three groups of 20 patients each.  In group A, complete aspiration of seroma by the way of a wide bore percutaneous cannula was done, followed by erythromycin injection in the seroma cavity (2gm in 40cc sterile water) and then the percutaneous  cannula was removed. In group B, 10 to 30ml of diluted  povidone iodine  10% solution  (50%  povidone  iodine

 

 

and 50% saline)  was administered by way of percutaneous catheter, which was  inserted under local anesthesia in the most dependent part  of  the  wound placed under ultrasound guidance. Patients were  then  instructed to irrigate the cavity 2 to 3 times daily with dilute povidone iodine solution at home, with a dwell time  of 20  to  30  minutes. In  group C, the proposed treatment was just the insertion of the percutaneous catheter with local infiltration placed under ultrasound guidance. In group B and  C, catheters were  removed later when output reached <20 ml/d.

Exclusion criteria included patients operated on with breast preservation procedures,  patients with wound infection, patients with known  or detected immediate hypersensitivity to erythromycin or to povidone iodine  detected by intradermal test (done by injection ofO.lml of erythromycin or diluted povidone iodine intradermally in the forearm region and waiting for 20-30 minutes, the test was positive when redness and wheel appeared). IS

 

Data collection procedure:

Data  were  collected from  the  patients' records. For every patient, we  obtained the following data: patient age, the  onset of postoperative mastectomy seroma, the number of aspirations of sero:ma before treatment, the onset of treatment. Patients were followed-up for a minimum of 3 months in the outpatient clinic of  the  department of  surgery. Post injection assessment included: Pain which was assessed using a linear visual analog pain score,19 daily assessment of  the  amount of catheter drainage and  clinical evaluation of seroma  cavity  1week, 3 weeks  , 6 weeks  and

3 months later.The seroma cavity was assessed by ultrasound examination to the mastectomy bed after  3 weeks. The development of any wound infection during the follow up was also reported.

 

Quality control:

All the steps were done under the authors' supervision and followed standard procedures. All  individuals agreed to participate after explaining the aims of the study and signed an

informed consent. The study was approved by the Local Ethics Committee.


 

Statistical analysis:

Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS version 17, Chicago, IL, USA). K-S  test of Normality was  done  for  quantitative data, which revealed not-normally distributed data so they were described using the median and range,  while qualitative data  were described using  frequency and percent. For comparing more than two groups, Kruskal Wallis test was applied while followed by  pairwise comparisons using multiple Mann-Whitney U test to compare between each  2 groups and significance level was adjusted after Bonferroni correction. Friedman ANOVA test  used  to compare quantitative data repeated more than

2 times. Comparing groups in qualitative data was done using the chi-square test but if invalid chi-square, the fisher's exact test was used for

2 x 2 tables and the Monte Carlo  significance test for (r x c) tables. All tests were two-sided and the significance level was set at 0.05 except in multiple pair wise comparison, the level of significance was  adjusted after Bonferroni correction at (0.017).

 

Power analysis:

Power  analysis is done using  NCSS 2004 and PASS 2000 Program. Sample  size of 20,

20,20 (tota160) achieves 86% power to detect difference among means of the  volume of drained fluid between the 3 groups, assuming that the common standard deviation is 143 at level of significance 0.05.

 

Results:

During the study period, we recruited a total of 60 female patients operated by modified radical mastectomy. The median age of the studied patients was 50 years (35-71 years). The median  age of group I was 49 years, for group II was 50 years, while for group III was

49 years, without significant difference between the 3 groups Table(l).

The onset of seroma after removal  of post­ mastectomy drains  was between 15-67 days. The median in group  A was 41 days (27- 67 days); in group B, it was 31.5  days  (18-  49 days), while in group  C, it was 37 days (15-

59  days). This  difference was  found to  be significant between group A and B (p= 0.001),

 

 

without significance difference between group

A and C and between group B and C Table(l).

The number of aspirations of seroma before treatment was 2 to 5 aspirations. The sixty patients began the treatment after 31-98 days from the onset of seroma.In group A, it was between 31-44 days with a median of 37 days, in group B,  it was between 34-62 days with a median of 43 days, while in group C, it was between 33-98 days with a median of 40 days Table(l).

In the follow up period, the volume of drained seroma is significantly reduced in each group over time. In group A, the median drainage volume before treatment was 400 cc, decreased at one week of erythromycin injection to become125 cc, and it decreased more to reach 25 cc  and 0 cc at the 3rd  and

6th week post-treatment  respectively.  This

difference was found  to be statistically significant (p<0.05). In group B, the median drainage volume before treatment was 475 cc, it declined to reach 20cc at one week of povidone iodine treatment and it decreased more to reach 0 cc and 0 cc, at the 3rd week and 6th week post-treatment respectively. This difference was found  to be statistically significant (p<0.05). Also, in group C, the median drainage volume before treatment was

425cc. The volumes of drainage declined to reach 50 and 0, Occ at 1st week , 3rd week, and 6th week respectively. This difference was found to be statistically  significant (p<0.05) Table(2).

Inall groups, the median amounts of seroma

fluid according to ultrasound examination (U/S) significantly decreased  from before treatment to 3rd week of follow up. In group A, before treatment the median amounts of seroma fluid was 300cc and became 1Occ. In group B, it was 375cc before treatment and became Occ and in group C the median was

325 cc and  became  Occ at 3rd week.  All differences were  found  to be statistically significant (p<O.OOl) Table(3).

Ingroup A, the median VAS was 7 ranging from 6-9 out of 10; the pain was burning in nature, last for 2-3 days, responding to ibuprofen and paracetamol. In both groups B and C, the median VAS was 1 ranging from

1-2, so there was no need for analgesics. The


 

VAS in both groups B and C was significantly lower  than  group  A (p<O.OOl) Table(4).

In our study, there were 5 cases of wound

infection (infected seroma). The incidence in group A was 5% (1 case). It happened on the

5th day post Erythromycin injection, there was turbid aspirate, it was sent to bacteriological analysis and the result was streptococcus pyogenus. It was sensitive to amoxicillin­ clavulanate potassium which was given and drain was inserted to drain the pus and was removed after 14 days.In group B and C, the incidence was 10% (2 cases) in each, it happened on the 4th day and 6th day from starting treatment in group B and it developed on the 5th and 6th days of drain insertion in group C. The color of drainage was turbid, povidone iodine was injected in both groups through the drain and amoxicillin - clavulanate potassium was given according to culture and sensitivity. The condition improved and the drain was removed on the 17th and 21st day in group Band on the 16th and 27th days in group C Table(5).

Catheter Drains were inserted in group B and C. In group B, the median time of drain removal was 8th day ranging from 4-17 days, while in group C the median time of drain removal was 14th day ranging from 6-35 days, (p=0.002) Table(6).

In group A, there were 8 cases of recurrent seroma after 3 months out of 20 cases in the follow up period, 3 of them were small amount

50-1OOcc treated with single aspiration, 2 cases were treated with 3 aspirations;  each case repeated with an interval of one week. The volume of drainage ranged from 100-150cc on the first aspiration, while in the second aspiration the volume declined to reach 50-

75cc. The third aspiration volume reached 30-

35cc and in the remaining three cases the volume   of  drainage was  200-250cc. 3 aspirations were done but the drainage did not decline, so a new drain was inserted and povidone iodine was injected The drains were removed on 7th, lOth, 12th days respectively. There was no recurrence of seroma. In group B, there were 2 cases of recurrent seroma after

3 months out of 20 cases; the first case was treated with single aspiration, the volume of drainage  was 80cc of seroma fluid. In the

 

 

second case 2 repeated aspirations were done with 10 days interval, the volumes of drainage were 50 and 30cc respectively. In group C, there were 7 cases of recurrent seroma after 3 months out of 20 cases. 2 cases were treated with single aspiration, the volumes of drainage were 50-70cc.  3 cases were treated with 2 aspirations, in first aspirations the volumes of drainage were 70, 100, 120cc respectively of seroma fluid, in the second aspirations the


 

volumes of drainage were 30, 30, 50cc respectively. 1 case was treated with 3 aspirations, the volumes were 200, 100, 30cc respectively. The last case was treated with reinsertion  of a new drain after trials of 3 aspirations in which the volumes of drainage were 300, 250, 300cc. Povidone iodine was injected through the drain. The drain was removed on the 14th day. There was no recurrence.

 

 

 

 

 

Table (1): Comparison between the three studied groups.

 

Group A

{erythromycin injection)

GroupB

{povidone iodine injection)

Groupe

{control)

x2

(p value)

Age:

Range                                         37-67

Median                                         49

 

Onset of seroma (days):

Range                                         27-67

Median                                         41

pl p2

Number of aspirations before treatment:

Range                                           2-3

Median                                           2

 

Onset  of treatment (days):

Range                                         31-44

Median                                          38

z1{p)

z2 {p)

 

 

42-71

50

 

 

18-49

31.5

0.001**

 

 

 

 

2-5

2.5

 

 

34-62

43

3.094(0.002)**

 

 

35-67

49

 

 

15-59

37

0.032

0.194

 

 

2-5

2.0

 

 

33-98

37

0.204 (0.838)

2.622 (0.009)**

 

 

0.99

{0.610)

 

 

10.6

{0.004)

 

 

 

 

 

 

2.19

{0.334)

 

 

11.06 (0.004)*

 

xz: Chi square for Kruskal Wallis test.

p1: p value of Mann whitney U test between group A and other groups. p2: p value of Mann whitney U test between group Band group C.

*:Statistically significant at p0.05.

**Statistically significant at p0.017(after Bonferroni correction). Z1: Zfor Mann Whitney test between group A and other groups. Z2: Zfor Mann Whitney test between group Band group C.

 

 

Table (2): Comparison between the three studied groups according to volume of drained seroma fluid  before  and   after  treatment  at   lrst, 3rd   and   6th   weeks.

 

 

Drainage volume

Group A (erythromycin injection)

GroupB (povidone iodine injection)

Group C (control)

x?

(p value)

Before treatment:

Range

Median

 

At 1st week: Range Median

Zt (p) Z2(p)

AtJrdweek: Range Median

Zt (p)

z2 (p)

 

At 6th week: Range Median

X2 Fr (p)

 

 

150-850

400

 

 

 

0-450

125

 

 

 

 

 

0-550

25

 

 

 

 

 

 

0-300

0

42.5 {<0.001)*

 

 

250-2500

475

 

 

 

0-50

20

4.436 (<0.001)**

 

 

 

 

0-150

0

2.368 (0.018)*

 

 

 

 

0-100

0

47.6 (<0.001)*

 

 

250-1000

425

 

 

 

0-600

50

1.225 (0.221)

3.488 (<0.001)**

 

 

0-150

0

1.716 (0.086)

0.948 (0.343)

 

 

0-400

0

50.9 (<0.001)*

 

 

2.86 (0.239)

 

 

 

22.23 (<0.001)*

 

 

 

 

 

6.47 (0.039)*

 

 

 

 

 

5.786 (0.055)

 

xz: Chi square for Kruskal Wallis test.

Zt: Zfor Mann Whitney test between group A and other groups. Zt: Zfor Mann Whitney test between group Band group C.

X2 Fr: Chi square for FriedmanANOVA test.

: Statistically significant at p0.05.

**Statistically significant at p < 0.017(after Bonferroni correction).

 

 

Table (3): Comparison between the amounts ofseromajluid in the three studied groups according  to ultrasound examination (U/S) to mastectomy bed before treatment and at the Jrd week of foUow up.

 

Amount of

Seroma by U/S

Group A (erythromycin injection)

GroupB (povidone iodine injection)

Group C (control)

x?

(p value)

Before treatment:

Range

Median

 

3rdweek: Range Median

z (p)

 

 

100-750

300

 

 

0-400

10

 

3.692 (<0.001)*

 

 

150-600

375

 

 

0-150

0

 

3.932 (<0.001)*

 

 

200-700

325

 

 

0-250

0

 

3.931 (<0.001)*

 

 

0.341

 

 

 

 

0.052

 

X}: Chi square for Kroskal Wallis test.

Z : Z for Wilcoxon signed ranks test between preoperative and at the 3rd week.

*:Statistically significant at p0.05.

 

 

Table (4): Comparison between the three studied groups according to post- injection  pain.

 

Pain at injection site

Group A (erythromycin injection)

GroupB (povidone iodine injection)

Groupe

(control)

x.Z

(p value)

 

Range Median Zt (p)

z2 (p)

 

6-9

7

 

1-2

1

5.540 (<0.001)**

 

1-2

1

5.629 (<0.001)**

1.363 (0.173)

 

 

(<0.001)*

 

''I}: Chi square for Kroskal Wallis test.

Z1: Zfor Mann Whitney test between group A and other groups. Z2: Zfor Mann Whitney test between group Band group C.

: Statistically significant at p0.05.

**:Statistically significant at p0.017(after Bonferroni correction).

 

 

 

Table (5): Comparison between the three studied groups according to wound infection.

 

Wound

Infection

Group A (erythromycin injection)

GroupB (povidone iodine injection)

Groupe

(control)

 

 

MCp

 

no.          %

no.          %

no.          %

 

 

 

1000

 

No

Yes

19        (95)

1          (5)

18        (90)

2          (10)

18        (90)

2         (10)

 

MCp: p for Monte Carlo significance test.

 

 

Table (6): Comparison between group B and C according to time of drain removal after treatment of seroma.

 

 

Drain removal time

 

GroupB (povidone iodine injection)

 

Group C (control)

z

(p)

 

Range

Median

 

4-17

8

 

6-35

14

 

3.143 (0.002)*

 

Z: Z for Mann Whitney test between group B and group C.

*:Statistically significant at p0.05.

 

 

Table (7): Comparison between the three studied groups according to the recu"ence of seroma after 3 months of complete treatment of seroma.

 

Follow up at

3rdmonth

Group A (erythromycin injection)

GroupB (povidone iodine injection)

Groupe

(control)

 

 

y,.Z (p)

 

no.          %

no.          %

no.          %

 

 

 

5.089 (0.079)

 

No seroma

 

Recurrence ofseroma

 

12        (60)

 

8         (40)

 

18        (90)

 

2          (10)

 

13        (65)

 

7         (35)

·x}: Chi square test.

 

 

 

Discussion:

MRM was associated with a higher rate of postoperative seroma formation.4 Seroma management should be  considered early because of the  tendency to develop complications and  impair  quality of  life. Indication for sclerotherapy primarily consisted of recurrent seroma despite failed aspiration.

In  this  study, there  was  no  statistical significant difference regarding the number of aspirations of seroma before treatment between the three groups (p= 0.33). This result was comparable to the  results reported by Throckmorton,13 and  Ali-Khan,12 where the range of aspirations was  1-5 and 2-7, respectively. Also,  when  we compare the volumes of drained seroma before treatment, there was no statistical significant difference between the three studied groups (p= 0.239). But at the end of the 1st week from starting treatment,  there was statistically significant decline in the volume of drained seroma in group B than  groups A (p<O.OOI) and  C (p<O.OOI), with  no  statistical significant


difference between groups A and C (p=0.221). Also at the 3rd week of follow up there was statistically significant difference in the volume of drained seroma between groups A and B (p=0.018). Povidone iodine  injection was significantly effective in  seroma volume reduction than  erythromycin injection. illtrasound examination to mastectomy bed at the 3rd week of follow up confirmed also the good response of patients in groups B and C than group A. This difference was found to be of borderline significance (p=0.052). In each group separately, there is a significant reduction of the drained amount of seroma both clinically and by U/S before and after treatment, p<0.05.

In the work of Throckmorton,13 the mean

volume of drainage across all patients in this series  was 105 cc (20 to 31Occ) which  was decreasing till complete cure by the 4th week. In this study ninety-five percent ethyl alcohol or povidone iodine was used as sclerotherapy. In the work of Ali Khan et al,12 the mean volume of drainage before treatment was 385 cc ranging from 170-1200 cc, the three out of

 

 

four patients were completely free on the follow up, and the average volume of 4th patient on follow up was 68 ranging from 50-200cc. In this study erythromycin was  used as sclerotherapy.

The   severity  of   pain  on   injecting

erythromycin was from moderate to severe. The median VAS was 7 (6-9),  the pain was burning  in nature, lasted  for 2-3  days  and responded to ibuprofen and paracetamol. The pain was due to severe irritation of the nerve endings. The pain in group B and C was in the form  of mild severity  (VAS  was 1 ranging from 1-2) and there was no need for analgesics. This difference  was found to be statistically significant   (p<O.OOl). In  the   work  of Throckmorton et al,13 minor degree  of pain was reported. In the work of Ali khan,12 there was some discomfort that had persisted for 72 hrs but was controlled with paracetamol  and ibuprofen.

Despite the presence of drains inboth groups

B and C, the rate of wound infection in both groups  was not significantly different  from that of group A. The incidence in group A was

5% (1 case), while the incidence in groups B and C was 10% (2 cases) in each.In the work of  Throckmorton,13 43%  developed an infection  at a median of 11 days (range 4 to

29)  after  the initiation of sclerotherapy treatment, while in the work of Ali khan,12 no wound infection was developed.

A good point in our study is the early removal of drains in group B in comparison to group C (8th  day  versus 14th  day, respectively) and this difference was found to be statistically significant (p==0.002). The uses of povidone iodine significantly decrease the time  of drain  removal. In Throckmorton study,13 the total median treatment  duration was 16 days (range 6 to 41).

The incidence of seroma recurrence in group B was 10%, which was lower than groups A and C (40 and  35%  respectively), but this difference doesn't reach   to  the  level  of significance.In the work of Throckmorton,13 treatment  was successful in 15 of 18 (83%) patients; 3 seromas recurred and were effectively treated  with  a single aspiration, while in the work of Ali-Khan et al,12 treatment was successful in 3 patients while in the last


 

one 8 aspirations were performed till complete cure. Recurrent seroma was treated in most of our cases with repeated aspirations except in

4 patients  (3 in group  A and 1 in group  C)

where  drain  reinsertion was  applied and povidone iodine was injected.

Our study has several limitations; seroma formation  was not studied in relation  to the predisposing factors to its formation as age of the patient, breast volume, nodal involvement, preoperative chemotherapy, surgical instrument (electrocautery or scalpel), use of pressure garment  and duration of drainage. Although in  a  previous study4  no  relationship was observed between the incidence of seroma and the patients' age, tumour size, and lymph node status. But in Gonzalez study,20 they showed that there was a direct correlation between age and the development of seroma. In Loo and Chow study,21 the presence of hypertension in a patient over 45 years should alert the surgeon to  possible seroma formation, particularly when the post-operative drainage exceeded 500  ml  in  the  first  three  days.

In conclusion, sclerotherapy is a feasible treatment for refractory seroma after MRM. The results of our study suggest that povidone iodine injection in patients with seroma after MRM  is an alternative solution in treating safely and rapidly refractory seroma with less recurrence and less  pain. Longer  treatment duration was  associated with  infection; antibiotic prophylaxis  should be considered.

 

References:

1- Chilson TR, Chan FD, Lonser RR, Wu TM, Aitken DR:  Seroma formation after modified radical  mastectomy. Am Surg

1992; 58: 750-754.

2- Woodworth PA, McBoyle MF, Helmer SD, Beamer RL:Seroma formation after breast cancer surgery: Incidence  and predicting factors. Am Surg  2000; 66:  444-450.

3- Kuroi K, Shimozuma  K, Taguchi  T, Imai

H, Yamashiro H, Ohsumi S, Saito  S: Pathophysiology of seroma in breast cancer. Breast  Cancer  2005;  12(4): 288-293.

4- Hashemi E, Kaviani A, Najafi M, Ebrahimi

M, Hooshmand  H, Montazeri A: Seroma formation after surgery for breast cancer. Breast Cancer  2004; 9(2): 44.

 

 

5- Kuroi K, Imai H, Yamashiro H, Ohsumi S, Saito S: Effect of mechanical  closure  of dead space on seroma formation after breast surgery. Breast Cancer 2006; 13(3): 260-

265.

6- Rice DC, Morris SM, Sarr MG, Farnell MB, van Heerden JA, Grant CS, Rowland CM, Ilstrup DM, Donohue  JH: Intraoperative topical tetracycline sclerotherapy following mastectomy: A prospective,  randomized trial. J Surg Oncol2000;  73(4): 224-227.

7- Carless PA, Henry DA: Systematic review and meta-analysis of the use of fibrin sealant to prevent seroma formation  after breast cancer surgery. BrJ Surg 2006; 93(7): 810-

819.

8- Chintamani, Singhal V, Singh J, Bansal A, Saxena S: Halfversus full vacuum suction drainage after modified radical mastectomy for breast cancer- a prospective randomized clinical  trial.  BMC Cancer 2005;  5: 11.

9- Wiener M, Mackie I, Ralston DR: Drainage of large or symptomatic seromas: Let the vacuum do the work. J Plast Reconstr Aesthet Surg  2007; 60(5): 573-574.

10-Stanczyk M,  Grala  B, Zwierowicz T,

Maruszynski M: Surgical resection for persistent seroma, following modified radical mastectomy. World J Surg Oneal

2007; 5: 104.

11-Butler CE: Treatment of refractory donor­ site seromas with percutaneous instillation of fibrin sealant. Plast Reconstr Surg 2006;

117(3): 976-985.

12-Ali-Khan AS,  Orlando  A,   Kenealy J: Erythromycin sclerotherapy in  the management  of seroma. J Plast Reconstr Aesthet  Surg   2009;  62(3):  55-58.

 

 

13-Throckmorton AD, Askegard-Giesmann J, Hoskin  TL, Bjarnason H, Donohue JH, Boughey JC, Degnim AC: Sclerotherapy for the treatment of postmastectomy seroma.AmJSurg2008; 196(4): 541-544.

14-Tang  X,  Cheng  D:   The   value  of

erythromycin pleurodesis in the treatment of malignant pleural effusions.J WestChina Univ   Med   Sci   1997; 28:   437-439.

15-Kafali  H,  Yurtseven  S,  Atmaca F: Management of non-neoplastic ovarian cysts with sclerotherapy. Int J Gynaecol Obstet 2003; 81: 41-45.

16-Agarwal R, Aggarwal AN, Gupta  D: Efficacy and safety of iodopovidone pleurodesis through  tube  thoracostomy. Respirology 2006;  11:  105-108.

17-Rivera M, Marcen R. Burgos J, Arranz M, Rodriguez R,    Teruel JL, Ortufio  J: Treatment  of posttransplant lymphocele with povidone-iodine sclerosis: Long-term follow-up. Nephron 1996; 74: 324-327.

18-Brockow K, Romano A, Aberer W, et al:

Skin testing in patients with hypersensitivity reactions  to iodinated contrast  media: A European multicenter study. Allergy 2009;

64(2): 234-241.

19-Revill  SI, Robinson  JO, Rosen M, Hogg MI: The reliability of a linear analogue for evaluating pain. Anaesthesia 1976; 31(9):

1191-1198.

20-Gonzalez EA, Saltzstein EC, Riedner CS, Nelson BK: Seroma formation following breast cancer surgery. Breast J 2003; 9:

385-388.

21-Loo  WT, Chow LW: Factors  predicting seroma  formation after  mastectomy for Chinese breast cancer patients. Indian J Cancer 2007; 44: 99-103.